Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Vivekanudeep,Karri

第一单位： Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA.;Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.

作者： Vivekanudeep,Karri ^[1] ; Howard,Lin ^[1] ; Jessica,Velazquez ^[1] ; Akanksha,Batajoo ^[1] ; Deevyashali,Parekh ^[1] ; Whitney,Stanton ^[1] ; Harshal,Abhyankar ^[1] ; Nader K,El-Mallawany ^[1] ; Jennifer,Agrusa ^[1] ; Olive,Eckstein ^[1] ; Nitya,Gulati ^[2] ; Jeffrey,Schwartz ^[3] ; Wendy,Woods-Swafford ^[4] ; Jaime,Boyd ^[5] ; Anikit,Saha ^[6] ; Carl E,Allen ^[1] ; Kenneth L,McClain ^[1]

作者单位： Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA.;Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA. ^[1] Department of Pediatrics, Weill Cornell Medical College, New York, New York, USA. ^[2] Studer Family Children's Hospital Pediatric Blood and Cancer, Pensacola, Florida, USA. ^[3] Unity Point Health, Blank Children's Hospital Cancer and Blood Disorders Clinic, Des Moines, Iowa, USA. ^[4] Pediatra Hematólogo y Oncólogo at Consultorios Royal Center, Panamá City, Panama. ^[5] Prisma Health Cancer Institute, Greenville, South Carolina, USA. ^[6]

关键词 Langerhans cell histiocytosis MAPK inhibition chemotherapy myeloid neoplasia